Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FAAH Inhibitor Trials Could Resume In US Following French Study Disaster Review

Executive Summary

Bial-Portela's drug had 'unique toxicity' not found with other compounds in the class, FDA says; findings could allow studies of Janssen's and Pfizer's investigational FAAH inhibitors that have been on hold to proceed.


Related Content

Phase I Trials: French Body Urges Transparency, Says Don't Just Follow The Rules
French Trial Tragedy: FDA Launches 'FAAH' Safety Probe
French Trial Tragedy: Janssen Halts FAAH Inhibitor Trial


Related Companies